Androgen deprivation therapy for prostate cancer

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 2, 2008, Pages 211-228

  Singer, Eric A ^a   Golijanin, Dragan J ^a   Miyamoto, Hiroshi ^a   Messing, Edward M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Androgen deprivation; Antiandrogen; Combined androgen blockade; Hormonal therapy; Intermittant androgen deprivation; Luteinizing hormone releasing hormone; Prostate cancer; Side effect

Indexed keywords

ABARELIX; ACETYLSALICYLIC ACID; ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLONIDINE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; DUTASTERIDE; ESTROGEN; FINASTERIDE; FLUTAMIDE; GABAPENTIN; GESTAGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; NILUTAMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PAROXETINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; RECOMBINANT ERYTHROPOIETIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMOXIFEN; TESTOSTERONE; UNINDEXED DRUG; VENLAFAXINE; VITAMIN D; WARFARIN;

ADJUVANT THERAPY; ADVANCED CANCER; ALCOHOL INTOLERANCE; ANAPHYLAXIS; ANEMIA; ANGINA PECTORIS; ANXIETY DISORDER; ARTHRALGIA; BLEEDING; BREAST TENDERNESS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CASTRATION; CHOLELITHIASIS; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; ESTROGEN BLOOD LEVEL; FATIGUE; FLU LIKE SYNDROME; GALLBLADDER DISEASE; GYNECOMASTIA; HAIR LOSS; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERPIGMENTATION; HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; INJECTION SITE REACTION; LIBIDO DISORDER; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; LUNG EMBOLISM; LUNG FIBROSIS; MALE SEXUAL DYSFUNCTION; MASTALGIA; METABOLIC SYNDROME X; METASTASIS; MONOTHERAPY; MOOD DISORDER; MUSCLE ATROPHY; MYALGIA; NAUSEA AND VOMITING; NONHUMAN; ORCHIECTOMY; OSTEOPENIA; OSTEOPOROSIS; PNEUMONIA; PROSTATE CANCER; PROSTATECTOMY; REPEATED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; STROKE; SURVIVAL TIME; TESTIS ATROPHY; TESTOSTERONE BLOOD LEVEL; THROMBOEMBOLISM; THROMBOSIS; VISUAL DISORDER; WEIGHT GAIN;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; HUMANS; MALE; ORCHIECTOMY; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 39049099889     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.2.211     Document Type: Review

References (163)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43-66
2. Huggins C, Hodges C. Studies on prostate cancer. I. The effects of castration, of estrogen and of androgen injection on serum phospatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7
3. Maatman TJ, Gupta MK, Montie JE. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate. J Urol 1985;133(4):620-1
4. Vacurg, Group Tvacur. Carcinoma of the prostate: Treatment comparisons. J Urol 1967;98:516-22
5. Vacurg, Group Tvacur. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967;124:1011-7
6. Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973;32(5):1126-30
7. Clark JA, Wray NP, Ashton CM. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. J Clin Oncol 2001;19(1):72-80
8. Blackard CE, Doe RP, Mellinger GT, Byar DP. Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate. Cancer 1970;26(2):249-56
9. Byar DP, Corle DK. Hormone therapy for prostate cancer, results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988;(7):165-70
10. Robinson MR, Smith PH, Richards B, et al. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group Phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol 1995;28(4):273-83
11. Bishop M. Experience with low-dose oestrogen in the treatment of advanced prostate cancer: a personal view. Br J Urol 1996;78:921-8
12. Shearer RJ, Hendry WF, Sommerville IF, Fergusson JD. Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer. Br J Urol 1973;45(6):668-77
13. Orlando M, Chacon M, Salum G, Chacon DR. Low-dose continuous oral fosfestrol is highly active in 'hormone-refractory' prostate cancer. Ann Oncol 2000;11(2):177-81
14. Malkowicz SB. The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001;58(2 Suppl 1):108-13
15. Klotz L, McNeill I, Fleshner N. A Phase I - II trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol 1999;161(1):169-72
16. Loblaw DA, Mendelson DS, Talcott JA, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004;22(14):2927-41
17. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004;61(4):332-53
18. Labrie F, Belanger A, Susan L, et al. History of LHRH agonist and combination therapy in prostate cancer. Endocr Relat Cancer 1996;3:243-78
19. Denis L. European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996. Urology 1998;51(5A Suppl):50-7
20. Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132(7):566-77
21. Tunn UW, Bargelloni U, Cosciani S, et al. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer. Urol Int 1998;60(Suppl 1):9-16; discussion 16-7
22. Dondi D, Limonta P, Moretti RM, et al. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res 1994;54(15):4091-5
23. Bubley GJ. Is the flare phenomenon clinically significant? Urology 2001;58(2 Suppl 1):5-9
24. Labrie F, Dupont A, Belanger A, Lachance R. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol 1987;138(4):804-6
25. Stege R. Potential side-effects of endocrine treatment of long duration in prostate cancer. Prostate Suppl 2000;10:38-42
26. Mongiat-Artus P, Teillac P. Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5(10):2171-9
27. Cook T, Sheridan WP. Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist 2000;5(2):162-8
28. Stricker HJ. Luteinizing hormone-releasing hormone antagonists in prostate cancer. Urology 2001;58(2 Suppl 1):24-7
29. Mcleod D, Zinner N, Tomera K, et al. A Phase III, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001;58(5):756-61
30. Tomera K, Gleason D, Gittelman M, et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001;165(5):1585-9
31. Plenaxis (abarelix for injectable suspension). Available from: http://www.fda.gov/cder/drug/infopage/plenaxis/default.htm. [Accessed 3 March 2007]
32. Goldenberg SL, Bruchovsky N. Use of cyproterone acetate in prostate cancer. Urol Clin North Am 1991;18(1):111-22
33. De Voogt HJ. The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer. Prostate Suppl 1992;4:91-5
34. Iversen P. Antiandrogen monotherapy: indications and results. Urology 2002;60(3 Suppl 1):64-71
35. De Voogt HJ, Smith PH, Pavone-Macaluso M, De Pauw M, Suciu S. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986;135(2):303-7
36. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25(12):1596-605
37. Wirth MP, Hakenberg OW, Froehner M. Antiandrogens in the treatment of prostate cancer. Eur Urol 2007;51(2):306-14
38. Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998;33(5):447-56
39. Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000;164(5):1579-82
40. Chatelain C, Rousseau V, Cosaert J. French multicentre trial comparing Casodex (ICI 176,334) monotherapy with castration plus nilutamide in metastatic prostate cancer: a preliminary report. Eur Urol 1994;26(Suppl 1):10-4
41. Boccardo F, Rubagotti A, Barichello M, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999;17(7):2027-38
42. See WA, Wirth MP, Mcleod DG, et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002;168(2):429-35
43. Iversen P, Johansson JE, Lodding P, et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004;172(5 Pt 1):1871-6
44. Schellhammer PF. An evaluation of bicalutamide in the treatment of prostate cancer. Expert Opin Pharmacother 2002;3(9):1313-28
45. Dole EJ, Holdsworth MT. Nilutamide: an antiandrogen for the treatment of prostate cancer. Ann Pharmacother 1997;31(1):65-75
46. Mcleod DG, Iversen P. Gynecomastia in patients with prostate cancer: a review of treatment options. Urology 2000;56(5):713-20
47. Delaere KP, Van Thillo EL. Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. Semin Oncol 1991;18(5 Suppl 6):13-8
48. Chang A, Yeap B, Davis T, et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 1996;14(8):2250-7
49. Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol 1996;155(1):209-12
50. Mcleod DG. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 1997;2(1):18-27
51. Sandow J, Von Rechenberg W, Engelbart K. Pharmacological studies on androgen suppression in therapy of prostate carcinoma. Am J Clin Oncol 1988;11(Suppl 1):S6-10
52. Geller J. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer. Semin Oncol 1985;12(1 Suppl 1):28-35
53. Labrie F, Dupont A, Giguere M, et al. Benefits of combination therapy with flutamide in patients relapsing after castration. Br J Urol 1988;61(4):341-6
54. Huggins C, Scott W. Bilateral adrenalectomy in prostate cancer: clinical features and urinary excretion of 17-ketosteroids and estrogen. Ann Surg 1945;122:1031-41
55. Schmitt B, Wilt TJ, Schellhammer PF, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 2001;57(4):727-32
56. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339(15):1036-42
57. Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 2000;92(21):1731-9
58. Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002;95(2):361-76
59. Group PCTC. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355:1491-8
60. Klotz L. Combined androgen blockade: an update. Urol Clin North Am 2006;33(2):161-6, v-vi
61. Kelly WK, Slovin S, Scher HI. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urol Clin North Am 1997;24(2):421-31
62. Kelly WK. Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. Eur Urol 1998;34(Suppl 3):18-23
63. Shi XB, Ma AH, Xia L, Kung HJ, De Vere White RW. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 2002;62(5):1496-502
64. Miyamoto H, Rahman M, Takatera H, et al. A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. J Biol Chem 2002;277(7):4609-17
65. Rahman MM, Miyamoto H, Lardy H, Chang C. Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. Proc Natl Acad Sci USA 2003;100(9):5124-9
66. Rahman MM, Miyamoto H, Takatera H, et al. Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells. J Biol Chem 2003;278(22):19619-26
67. Lee YF, Lin WJ, Huang J, et al. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Res 2002;62(21):6039-44
68. Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes Ann Rev Biochem 1994;63:25-61
69. Kaplan SA. 5alpha-reductase inhibitors: what role should they play? Urology 2001;58(6 Suppl 1):65-70; discussion 70
70. Ornstein DK, Smith DS, Andriole GL. Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed. Urology 1998;52(6):1094-7
71. Kirby R, Robertson C, Turkes A, et al. Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group. Prostate 1999;40(2):105-14
72. Leibowitz RL, Tucker SJ. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Oncologist 2001;6(2):177-82
73. Iversen P, Melezinek I, Schmidt A. Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU Int 2001;87(1):47-56
74. Mcleod DG, Iversen P, See WA, et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;97(2):247-54
75. Reese DM. Choice of hormonal therapy for prostate cancer. Lancet 2000;355(9214):1474-5
76. Iversen P, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998;51(3):389-96
77. Sternberg CN. Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme. BJU Int 2006;97(3):435-8
78. Iversen P. The third analysis of the bicalutamide Early Prostate Cancer programme. BJU Int 2006;97(3):438-9
79. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol 2006;175(1):27-34
80. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-7
81. Sato N, Gleave ME, Bruchovsky N, et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 1996;58(2):13946
82. Wright JL, Higano CS, Lin DW. Intermittent androgen deprivation: clinical experience and practical applications. Urol Clin North Am 2006;33(2):167-79, vi
83. Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986;58(11):2546-50
84. Gulley JL, Figg WD, Steinberg SM, et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized Phase III clinical trial using limited hormonal therapy. J Urol 2005;173(5):1567-71
85. Youssef E, Tekyi-Mensah S, Hart K, Bolton S, Forman J. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer. Am J Clin Oncol 2003;26(5):e119-23
86. Prapotnich D, Fizazi K, Escudier B, et al. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 2003;43(3):233-9; discussion 239-40
87. De Leval J, Boca P, Yousef E, et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002;1(3):163-71
88. Peyromaure M, Delongchamps NB, Debre B, Zerbib M. Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience. Urology 2005;65(4):724-9
89. De La Taille A, Zerbib M, Conquy S, et al. Intermittent androgen suppression in patients with prostate cancer. BJU Int 2003;91(1):18-22
90. Schow DA, Renfer LG, Rozanski TA, Thompson IM. Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J 1998;91(9):855-7
91. Karling P, Hammar M, Varenhorst E. Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol 1994;152(4):1170-3
92. Smith JA Jr. A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate. J Urol 1994;152(1):132-4
93. Smith JA Jr. Management of hot flushes due to endocrine therapy for prostate carcinoma. Oncology (Williston Park) 1996;10(9):1319-22; discussion 1324
94. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331(6):347-52
95. Langenstroer P, Kramer B, Cutting B, et al. Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer. J Urol 2005;174(2):642-5
96. Holzbeierlein JM. Managing complications of androgen deprivation therapy for prostate cancer. Urol Clin North Am 2006;33(2):18100, vi
97. Loprinzi CL, Pisansky TM, Fonseca R, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998;16(7):2377-81
98. Quella SK, Loprinzi CL, Sloan J, et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 1999;162(1):98-102
99. Adelson KB, Loprinzi CL, Hershman DL. Treatment of hot flushes in breast and prostate cancer. Expert Opin Pharmacother 2005;6(7):1095-106
100. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004;63(4):742-5
101. Basaria S, Lieb J II, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002;56(6):779-86
102. Tyrrell CJ, Payne H, Tammela TL, et al. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys 2004;60(2):476-83
103. Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005;23(4):808-15
104. Fradet Y, Egerdie B, Andersen M, et al. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur Urol (2007)52(1):106-14
105. Melton LJ III, Alothman KI, Khosla S, et al. Fracture risk following bilateral orchiectomy. J Urol 2003;169(5):1747-50
106. Morote J, Martinez E, Trilla E, et al. Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol 2003;44(6):661-5
107. Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol 2007;177(1):17-24
108. Smith MR, Fallon MA, Goode MJ. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology 2003;61(1):127-31
109. Body JJ. Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 2001;28(4 Suppl 11):49-53
110. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004;9(Suppl 4):28-37
111. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23(34):8580-7
112. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102(4):433-41
113. Onwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343(9):604-10
114. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345(13):948-55
115. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169(6):2008-12
116. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006;24(24):3979-83
117. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97
118. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365(9468):1415-28
119. Lu-Yao G, Stukel TA, Yao SL. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol 2004;171(6 Pt 1):2285-90
120. Nishiyama T, Ishizaki F, Anraku T, Shimura H, Takahashi K. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 2005;90(2):657-60
121. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001;86(9):4261-7
122. Yannucci J, Manola J, Garnick MB, et al. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol 2006;176(2):520-5
123. Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110(7):1493-500
124. Holzbeierlein JM, Castle EP, Thrasher JB. Complications of androgen-deprivation therapy for prostate cancer. Clin Prostate Cancer 2003;2(3):147-52
125. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003;61(2 Suppl 1):32-8
126. Information for Healthcare Professionals. Erythropoiesis Stimulating Agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]. Available from: http://www.fda.gov/cder/drug/InfoSheets/ HCP/RHE2007HCP.htm. [Accessed 3 September 2007]
127. Green HJ, Pakenham KI, Headley BC, et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 2002;90(4):427-32
128. Salminen EK, Portin RI, Koskinen A, Helenius H, Nurmi M. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res 2004;10(22):7575-82
129. Joly F, Alibhai SM, Galica J, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol 2006;176(6 Pt 1):2443-7
130. Cherrier MM, Rose AL, Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol 2003;170(5):1808-11
131. Salminen EK, Portin RI, Koskinen AI, Helenius HY, Nurmi MJ. Estradiol and cognition during androgen deprivation in men with prostate carcinoma. Cancer 2005;103(7):1381-7
132. Gleave ME, Sato N, Goldenberg SL, et al. Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model. J Urol 1997;157(5):1727-30
133. Schulman CC, Debruyne FM, Forster G, et al. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000;38(6):706-13
134. Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002;167(1):112-6
135. Aus G, Abrahamsson PA, Ahlgren G, et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int (2002) 90(6):561-6
136. Klotz LH, Goldenberg SL, Jewett MA, et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003;170(3):791-4
137. Gleave ME, Goldenberg SL, Chin JL, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001;166(2):500-6; discussion 506-7
138. Gleave ME, Goldenberg SL, Chin J, Al E. Randomized comparative study of 3 vs. 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy: 3 year PSA recurrence rates. J Urol 2003:169
139. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007;177(6):2106-31
140. Roach M III, Izaguirre A. Goserelin acetate in combination with radiotherapy for prostate cancer. Expert Opin Pharmacother 2007;8(2):257-64
141. Laverdiere J, Gomez JL, Cusan L, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;37(2):247-52
142. D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292(7):821-7
143. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005;6(11):841-50
144. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997;15(3):1013-21
145. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a Phase III randomised trial. Lancet 2002;360(9327):103-6
146. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21(21):3972-8
147. Granfors T, Modig H, Damber JE, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998;159(6):2030-4
148. Bolla M, Artignan X, Fourneret P, et al. Neoadjuvant hormonal treatment combined with external irradiation in the management of prostate cancer. Bull Cancer 2006;93(11):1101-5
149. Roach M, Lu J, Pilepich MV, Al E. Predicting long term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000;47:617-27
150. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997;79(2):235-46
151. Kirk D. Immediate vs. deferred hormone treatment for prostate cancer: how safe is androgen deprivation? BJU Int 2000;86(Suppl 3):220
152. Kawakami J, Cowan JE, Elkin EP, et al. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 2006;106(8):1708-14
153. Chodak GW, Keane T, Klotz L. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 2002;60(2):201-8
154. Wirth MP, See WA, McLeod DG, et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004;172(5 Pt 1):1865-70
155. Graff JN, Mori M, Li H, et al. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. J Urol 2007;177(4):1307-12
156. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352(19):1977-84
157. Johansson JE, Adami HO, Andersson SO, et al. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992;267(16):2191-6
158. Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006;24(12):1868-76
159. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341(24):1781-8
160. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472-9
161. Messing E, Manola J, Sarosdy M, et al. Immediate hormonal therapy combined with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer: results at 10 yearst of EST 3886. J Urol 2003;169(Suppl 4):396
162. Jordan WP Jr, Blackard CE, Byar DP. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma, South Med J 1977;70(12):1411-3
163. Madeb R, Golijanin D, Messing E. Early versus late hormone treatment of metastatic prostate cancer. In: Dawson C, et al., editors. The Evidence for Urology. Barnes, Shrewsbury, UK:Castle Hill; 2004. p. 165-80